共 50 条
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning
被引:150
|作者:
Boelens, Jaap Jan
[1
]
Aldenhoven, Mieke
[1
]
Purtill, Duncan
[2
]
Ruggeri, Annalisa
[2
]
DeFor, Todd
[3
]
Wynn, Robert
[4
]
Wraith, Ed
[5
]
Cavazzana-Calvo, Marina
[6
,7
]
Rovelli, Attilio
[8
]
Fischer, Alain
[6
]
Tolar, Jakub
[3
]
Prasad, Vinod K.
[9
]
Escolar, Maria
[10
]
Gluckman, Eliane
[2
]
O'Meara, Anne
[11
]
Orchard, Paul J.
[3
]
Veys, Paul
[12
]
Eapen, Mary
[13
]
Kurtzberg, Joanne
[9
]
Rocha, Vanderson
[2
,14
]
机构:
[1] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, NL-3584 EA Utrecht, Netherlands
[2] Eurocord Hop St Louis, Dept Hematol BMT, Paris, France
[3] Univ Minnesota, Program Blood & Marrow Transplantat, Minneapolis, MN USA
[4] Royal Manchester Childrens Hosp, Dept Hematol BMT, Manchester M27 1HA, Lancs, England
[5] St Marys Hosp, Manchester Acad Hlth Sci Ctr Genet Med, Manchester M13 0JH, Lancs, England
[6] Hop Univ Necker Enfants Malad, AP HP, Dept Biotherapie, Paris, France
[7] Univ Paris 05, Sorbonne Paris Cite, IMAGINE Inst, Paris, France
[8] Univ Milano Bicocca, Pediat Clin, Ctr Trapianto Midollo Osseo Fdn MBBM, Monza, Italy
[9] Duke Univ, Div Pediat Blood & Marrow Transplantat, Durham, NC USA
[10] Univ Pittsburgh, Program Study Neurodev Rare Disorders, Pittsburgh, PA USA
[11] Our Ladys Childrens Hosp, Dept Hematol & BMT, Dublin, Ireland
[12] Great Ormond St Hosp Sick Children, Blood & Marrow Transplantat Program, London, England
[13] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
[14] Oxford Univ Hosp, Oxford, England
来源:
关键词:
CORD BLOOD TRANSPLANTATION;
ENZYME-REPLACEMENT THERAPY;
RISK-FACTOR ANALYSIS;
BONE-MARROW;
PEDIATRIC-PATIENTS;
GRAFT;
DISEASE;
COMBINATION;
D O I:
10.1182/blood-2012-09-455238
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at day 100 was 25%, and chronic GVHD and 5 years was 16%. Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, respectively. EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelated cord blood (CB) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor. EFS was lower after transplantation in 4/6 matched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007). Full-donor chimerism (P = .039) and normal enzyme levels (P = .007) were higher after CB transplantation (92% and 98%, respectively) compared with the other grafts sources (69% and 59%, respectively). In conclusion, results of allogeneic transplantation for HS are encouraging, with similar EFS rates after MSD, 6/6 matched UCB, 5/6 UCB, and 10/10 matched UD. The use of mismatched UD and 4/6 matched UCB was associated with lower EFS.
引用
收藏
页码:3981 / 3987
页数:7
相关论文